Avricore Health (DB:8VP1) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

8VP1 Overzicht aandelen

Avricore Health Inc. houdt zich bezig met gezondheidsgegevens en point-of-care technologieën in Canada.

8VP1 fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De winst is de afgelopen 5 jaar met 30.2% per jaar gegroeid

Risicoanalyse

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

Heeft geen betekenisvolle marktkapitalisatie ( €18M )

Heeft geen zinvolle omzet ( CA$4M )

Avricore Health Inc. Concurrenten

MeVis Medical Solutions

XTRA:M3V

€44.0m

DocCheck

XTRA:AJ91

€42.9m

CompuGroup Medical SE KGaA

XTRA:COP

€726.9m

Nexus

XTRA:NXU

€913.3m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Avricore Health
Historische aandelenkoersen
Huidige aandelenkoers	CA$0.13
52 Week Hoogtepunt	CA$0.20
52 Week Laag	CA$0.073
Bèta	-1.88
11 maand verandering	-27.33%
3 maanden verandering	14.68%
1 Jaar Verandering	12.61%
33 jaar verandering	22.55%
5 jaar verandering	1,288.89%
Verandering sinds IPO	-90.30%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	8VP1	DE Healthcare Services	DE Markt
7D	12.6%	-2.2%	-1.9%
1Y	12.6%	19.1%	12.3%

Rendement versus industrie: 8VP1 presteerde slechter dan de German Healthcare Services -sector, die het afgelopen jaar een rendement van 18.5 % opleverde.

Rendement versus markt: 8VP1 kwam overeen met de German markt, die het afgelopen jaar een rendement opleverde van 12.8 %.

Prijsvolatiliteit

Is 8VP1's price volatile compared to industry and market?
8VP1 volatility
8VP1 Average Weekly Movement	17.4%
Healthcare Services Industry Average Movement	5.8%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	10.7%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: De aandelenkoers van 8VP1 is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 17% ) van 8VP1 is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen German.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1996	n/a	Hector Bremner	avricore.com

Avricore Health Inc. houdt zich bezig met gezondheidsgegevens en point-of-care technologieën in Canada. Het bedrijf levert HealthTab, een kant-en-klaar point-of-care testplatform dat apotheken verandert in diagnostische centra in de gemeenschap. Het bedrijf was voorheen bekend als Vanc Pharmaceuticals Inc. en veranderde zijn naam in Avricore Health Inc. in oktober 2018.

Avricore Health Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Avricore Health zich tot de beurswaarde?
8VP1 fundamentele statistieken
Marktkapitalisatie	€12.87m
Inkomsten(TTM)	-€1.96k
Inkomsten(TTM)	€3.01m

4.3x

P/S-verhouding

-6,570x

Koers/Winstverhouding

Is 8VP1 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
8VP1 resultatenrekening (TTM)
Inkomsten	CA$4.48m
Kosten van inkomsten	CA$2.86m
Brutowinst	CA$1.62m
Overige uitgaven	CA$1.62m
Inkomsten	-CA$2.92k

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.000029
Brutomarge	36.16%
Nettowinstmarge	-0.065%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde 8VP1 op de lange termijn?

Bekijk historische prestaties en vergelijking

8VP1 Overzicht aandelen

Beloningen

Risicoanalyse

Avricore Health Inc. Concurrenten

XTRA:M3V

€44.0m

XTRA:AJ91

€42.9m

XTRA:COP

€726.9m

XTRA:NXU

€913.3m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Second quarter 2024 earnings released: EPS: CA$0.001 (vs CA$0.003 loss in 2Q 2023)

First quarter 2024 earnings released: EPS: CA$0.002 (vs CA$0.002 loss in 1Q 2023)

Full year 2023 earnings released: CA$0.007 loss per share (vs CA$0.008 loss in FY 2022)

Avricore Health Inc., Annual General Meeting, Jun 20, 2024

New major risk - Market cap size

Insufficient new directors

Recent updates

Second quarter 2024 earnings released: EPS: CA$0.001 (vs CA$0.003 loss in 2Q 2023)

First quarter 2024 earnings released: EPS: CA$0.002 (vs CA$0.002 loss in 1Q 2023)

Full year 2023 earnings released: CA$0.007 loss per share (vs CA$0.008 loss in FY 2022)

Avricore Health Inc., Annual General Meeting, Jun 20, 2024

New major risk - Market cap size

Insufficient new directors

Third quarter 2023 earnings released: CA$0.003 loss per share (vs CA$0.002 loss in 3Q 2022)

Avricore Health Inc. Expands Its Innovative Point-Of-Care Chronic and Infectious Disease Screening and Health- Data Management Platform, Healthtab

Second quarter 2023 earnings released: CA$0.003 loss per share (vs CA$0.002 loss in 2Q 2022)

Avricore Health Inc. Announces Board Changes

First quarter 2023 earnings released: CA$0.002 loss per share (vs CA$0.002 loss in 1Q 2022)

Avricore Health Inc., Annual General Meeting, Jun 21, 2023

Full year 2022 earnings released: CA$0.008 loss per share (vs CA$0.018 loss in FY 2021)

Third quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.005 loss in 3Q 2021)

Second quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.004 loss in 2Q 2021)

High number of new directors

First quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.009 loss in 1Q 2021)

Avricore Health Inc., Annual General Meeting, Jul 21, 2022

High number of new and inexperienced directors

Full year 2021 earnings released: CA$0.018 loss per share (vs CA$0.019 loss in FY 2020)

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Avricore Health Inc Begins Patient Testing on the HealthTab™ Platform in Select Shoppers Drug Mart® Pharmacies

Second quarter 2021 earnings released: CA$0.004 loss per share (vs CA$0.003 loss in 2Q 2020)

Avricore Health Inc. Patient Testing Has Begun on the First Deployment of the New HealthTab

Avricore Health Inc. Begins Patient Testing on First Deployment of New HealthTabTM-Integrated Afinion 2TM Analyzers in Initial Shoppers Drug Mart® Pharmacy Location

Avricore Health Inc. Signs Master Agreement to Pilot Healthtab Platform for Diabetes Management in Select Shoppers Drug Mart Pharmacies

Avricore Health Inc. Successfully Launches HealthTab™ in the First of 11 Shoppers Drug Mart Pilot Locations

Avricore Health's HealthTab Achieves Critical Milestones in Connecting New Testing Device

First quarter 2021 earnings released: CA$0.01 loss per share (vs CA$0.004 loss in 1Q 2020)

Full year 2020 earnings released: CA$0.019 loss per share (vs CA$0.041 loss in FY 2019)

Avricore Health Inc. Signs Letter of Intent with Avrok Laboratories

Avricore Health Inc. announced that it has received CAD 1.54 million in funding

Whole Health Pharmacy Partners to Launch Avricore’s Healthtab™

New 90-day high: €0.36

Avricore Health Inc. announced that it expects to receive CAD 1.54 million in funding

Avricore Health Inc. Announces Board Changes

Avricore Health Inc. announced that it has received CAD 1.5 million in funding

Avricore Health Inc. Successfully Intergrates ID Now™ Rapid PCR Test Device, Offering Real-Time Covid-19 Reporting Direct from Instrument for First Time

Avricore Health Announces Management Changes

Third quarter 2020 earnings released: CA$0.003 loss per share

Avricore Health Inc. announced that it expects to receive CAD 1.5 million in funding

Healthtab Integrating New Device to Add Hba1c Blood Glucose Testing to Its Real-Time Data Reporting System